Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
41 studies found for:    " June 15, 2011":" July 15, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" June 15, 2011":" July 15, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Connect to Protect (C2P): Building a Community-Based Infrastructure for HIV Prevention
Condition: HIV Infection
Intervention: Behavioral: Community Mobilization
2 Completed Residual Risk Assessment Of HIV Transmission
Condition: HIV Infection
Intervention: Biological: blood and semen sampling, specific biological exams and biobank and self administered questionnaires
3 Completed Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials
Condition: HIV Infections
Interventions: Biological: Sub C gp140 Vaccine;   Biological: MF59C.1 Adjuvant
4 Completed Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Condition: HIV Infection
Intervention:
5 Active, not recruiting
Has Results
REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
Condition: HIV Infection
Interventions: Drug: Atripla (r);   Drug: Efavirenz;   Drug: Truvada;   Drug: Rifampin/isoniazid/pyrazinamide/ethambutol FDC;   Drug: Rifampin/isoniazid FDC;   Drug: Isoniazid
6 Withdrawn Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women
Condition: HIV Infected
Intervention: Drug: Tenofovir, Emtricitabine, Atazanavir, Ritonavir
7 Completed Vitamin D HIV Study
Condition: HIV
Interventions: Drug: Vitamin D3;   Drug: Placebo
8 Completed Genetics and HIV-1 Protease Inhibitors
Condition: HIV
Intervention: Drug: Atazanavir
9 Completed Discontinuation of Primary and Secondary Prophylaxis for Opportunistic Infections in HIV-infected Patients
Condition: HIV Infection
Intervention: Other: Discontinuation of prophylactic drugs i.e. co-trimoxazole, dapsone, fluconazole, itraconazole, azithromycin
10 Completed Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
Condition: HIV Prevention
Interventions: Drug: Tenofovir gel;   Drug: Universal placebo gel
11 Completed Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia
Condition: HIV
Intervention: Drug: Unique
12 Completed Urban Health Study II
Condition: HIV
Interventions: Behavioral: Standard Referral;   Behavioral: Project Bridge
13 Completed A Parenting and Self-Care Intervention for HIV Infected Mothers
Condition: HIV
Intervention: Behavioral: IMAGE Intervention
14 Completed Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir
Condition: Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions: Drug: Dolutegravir 50 mg tablet;   Drug: Dolutegravir 50 mg oral granules
15 Completed Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics
Condition: HIV
Intervention: Drug: zidovudine 300mg and lamivudine 150mg as Combivir
16 Completed Maraviroc Switch Collaborative Study
Condition: HIV
Intervention: Drug: Maraviroc
17 Completed HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies
Condition: HIV
Interventions: Behavioral: Monetary Incentive;   Behavioral: Questionnaire Timing;   Behavioral: HIV Test Offering
18 Completed
Has Results
A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients
Condition: Human Immunodeficiency Virus 1
Interventions: Drug: Darunavir(DRV);   Drug: Ritonavir;   Drug: 2 nucleoside reverse transcriptase inhibitors (NRTIs)
19 Unknown  Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
20 Active, not recruiting HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Condition: Human Immunodeficiency Virus-1
Interventions: Drug: BMS-663068;   Drug: Raltegravir;   Drug: Tenofovir;   Drug: Ritonavir;   Drug: Atazanavir

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.